Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of company-specific momentum and sector positioning rather than one single headline. Investors may be reacting to Alnylam’s recent neuroscience update, the scheduled July 30, 2026 second-quarter earnings report, and the company’s strengthened standing in ATTR-CM after a rival late-stage study failed earlier this month.

Details:

Alnylam said on July 16 that it will report second-quarter 2026 results before the market opens on July 30, which can lift shares as investors position for a business update and fresh guidance.

The company’s July 15 neuroscience update highlighted the start of a global Phase 2 study of mivelsiran in Down syndrome-associated Alzheimer’s disease and the completion of enrollment in a Phase 2 study in cerebral amyloid angiopathy.

In first-quarter 2026 results, Alnylam said total net product revenue topped $1 billion, with AMVUTTRA and ONPATTRO together generating $910 million, reinforcing the strength of its commercial base.

This could also be because the ATTR-CM landscape became more favorable after a competing heart-disease program from AstraZeneca and Ionis failed to meet its primary endpoint in a late-stage trial on July 9, reducing a key overhang for Alnylam’s franchise.

Sources:

Alnylam, SEC, STAT

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ALNY Insider Trading Activity

$ALNY insiders have traded $ALNY stock on the open market 136 times in the past 6 months. Of those trades, 0 have been purchases and 136 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 19 sales selling 16,690 shares for an estimated $5,332,821.
PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 32 sales selling 15,074 shares for an estimated $4,883,227.
KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 28 sales selling 8,541 shares for an estimated $2,754,438.
JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 19 sales selling 6,916 shares for an estimated $2,215,352.
TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 19 sales selling 5,866 shares for an estimated $1,877,015.
MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ALNY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ALNY Hedge Fund Activity

We have seen 346 institutional investors add shares of $ALNY stock to their portfolio, and 407 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 5,499,424 shares (-33.7%) from their portfolio in Q1 2026, for an estimated $1,819,594,418
CAPITAL RESEARCH GLOBAL INVESTORS added 2,691,473 shares (+39.7%) to their portfolio in Q1 2026, for an estimated $890,527,671
TWO SIGMA INVESTMENTS, LP added 1,376,457 shares (+223.4%) to their portfolio in Q1 2026, for an estimated $455,428,327
FMR LLC removed 1,322,983 shares (-8.3%) from their portfolio in Q1 2026, for an estimated $437,735,385
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,127,162 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $372,944,090
CLEARBRIDGE INVESTMENTS, LLC added 759,023 shares (+127.1%) to their portfolio in Q1 2026, for an estimated $251,137,940
MANUFACTURERS LIFE INSURANCE COMPANY, THE added 598,953 shares (+944.5%) to their portfolio in Q1 2026, for an estimated $198,175,579

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 06/29/2026
B of A Securities issued a "Buy" rating on 01/30/2026

To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

$ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 12 analysts offer price targets for $ALNY in the last 6 months, with a median target of $427.0.

Here are some recent targets:

Patrick R. Trucchio from HC Wainwright & Co. set a target price of $470.0 on 06/29/2026
Eric Joseph from Citigroup set a target price of $380.0 on 05/19/2026
Luca Issi from RBC Capital set a target price of $445.0 on 05/01/2026
Derek Archila from Wells Fargo set a target price of $377.0 on 05/01/2026
Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.